



Aalborg Universitet

AALBORG UNIVERSITY  
DENMARK

## DESCRIPTIVE STUDY OF RENAL IMPAIRMENT IN PATIENTS WITH OSTEOPOROSIS IN DENMARK

Hansen, Louise; Eriksen, Stine Aistrup; Krishna, Arun; Jørgensen, Andreas D.; Vestergaard, Peter

*Publication date:*  
2014

*Document Version*  
Accepted author manuscript, peer reviewed version

[Link to publication from Aalborg University](#)

*Citation for published version (APA):*  
Hansen, L., Eriksen, S. A., Krishna, A., Jørgensen, A. D., & Vestergaard, P. (2014). *DESCRIPTIVE STUDY OF RENAL IMPAIRMENT IN PATIENTS WITH OSTEOPOROSIS IN DENMARK*. Poster presented at WCO-IOF-ESCEO 2014, Sevilla, Spain.

### General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -

### Take down policy

If you believe that this document breaches copyright please contact us at [vbn@aub.aau.dk](mailto:vbn@aub.aau.dk) providing details, and we will remove access to the work immediately and investigate your claim.

# Descriptive study of renal impairment in patients with osteoporosis in Denmark

Louise Hansen<sup>1</sup>, Stine Aistrup Eriksen<sup>1</sup>, Arun Krishna<sup>2</sup>,  
Andreas D. Jorgensen<sup>3</sup>, Peter Vestergaard<sup>1</sup>

<sup>1</sup>Aalborg University, Aalborg, Denmark

<sup>2</sup>Merck & Co, Whitehouse Station NJ 08889, USA

<sup>3</sup>MSD Denmark, Ballerup, Denmark

Corresponding author: lhan@business.aau.dk

## Objective:

The purpose of this study was to estimate the prevalence of renal impairment for osteoporotic patients, and compare demographic characteristics for osteoporotic patients across level of renal impairment.

## Conclusion:

Based on eGFR<35, bisphosphonate treatment would not be recommended in 3.6 % of osteoporotic patients due to renal impairment.

## Material and methods:

This cohort study is based on data from the Danish national health registries and blood measurements of estimated Glomerular Filtration Rate (eGFR) from three of five Danish regions. Last blood measurement of eGFR is used as index-date.

The inclusion criteria were:

- age  $\geq 50$  years
- AND either diagnosed with osteoporosis
- OR had a history of fracture
- OR a bone mass density (BMD) t-score of lumbar spine or femur neck  $< -2.5$ .

Stages of renal impairment ranged from normal to failure (KDOQI 1-5) measured by eGFR and a separate category of 'not recommended for BIS treatment (eGFR <35) equivalent to some patients in KDOQI stage 3 and all patients in KDOQI stages 4 and 5.

## Results:

In total 7,336 patients were identified, of which 6,614 were women. The prevalence of renal failure (stage 5) amongst osteoporotic patients was 0.1%, and the prevalence of an eGFR<35 ('not recommended for BIS') was 3.6%. The median time from diagnosis of osteoporosis to measurement of eGFR was  $7.2 \pm 5.1$  years.

The mean age was  $72.5 \pm 10.3$  years. The age increased significantly with decreasing eGFR from  $69.0 \pm 10.1$  for stage 1 (normal) to  $81.5 \pm 7.6$  for stage 5 (failure) patients ( $p < 0.001$ ). Weight was significantly higher for KDOQI 3 (moderate renal impairment, eGFR 30-59) patients ( $p = 0.021$ ), while BMI similarly increased with decreasing eGFR ( $p < 0.001$ ).

For co-morbidities diabetes was significantly associated with decreased eGFR ( $p < 0.001$ ).